Orthopaedics Product Information
Bio-Technology
| |
| Bio-Technology
| | 
|
| | | Device Technologies are market leader’s in the provision of Autologous Chondrocyte Implantation. Utilising a 100% autologous materials and a collagen patch, Device Technologies partners Orthogen AG to provide this revolutionary technology.
Device Technologies strives to set the bench mark in service in this highly regulated arena through strict protocols, providing in theatre assistance at both biopsy and implantation stages of the process, to ensure an optimal outcome for the patient.
For more information about ACI please refer to the Orthogen AG website www.orthogen.dyndns.org/orthogen/en (Please note you are now leaving the Device Technologies Australian/New Zealand website and that other linked advertisements may not comply with the Code.)
Device Technologies is in the process of registering and launching the Arthrex Autologous Conditioned Plasma (ACP) System. ACP is set to revolutionise the world of acute minor soft tissue injury treatment. The wholly autologous growth factor and protein concentrations contained within ACP speed the soft tissue healing process through increasing native tenocyte proliferation and activity, along with other healing processes.
| | | For more information on please visit www.arthrex.com
Please note you are now leaving the Device Technologies Australian/New Zealand website and that other linked advertisements may not comply with the Code. | |
|
 | |
